Newsroom

[Politico] No consensus on how to afford specialty drugs

By Brett Norman May 21, 2014 The astronomical price of a new “miracle” drug for hepatitis C has insurers and others who ultimately foot health care […]

Read more

[Healthcare Payer News] Sovaldi spurs call to action on high drug costs

By Anthony Brino May 21, 2014   The breakthrough hepatitis drug Sovaldi has sparked a vigorous debate about the financial sustainability of U.S. healthcare and the […]

Read more

[Law360] Drugmakers, Insurers Battle Over Surging Big Pharma Prices

By Jeff Overly May 21, 2014   Executives representing drugmakers, employers and health insurers sparred Wednesday at a high-profile forum on soaring prescription drug prices, clashing […]

Read more

[Modern Healthcare] Excessive drug costs could invite price caps: AHIP’s Ignagni

By Paul Demko May 21, 2014   The steep cost of Sovaldi—Gilead Sciences’ $1,000-per-pill treatment for hepatitis C—is prompting wide-ranging discussions about the cost of drugs […]

Read more